Seres Therapeutics appoints Marella Thorell as CFO; David Arkowitz retires March 15

Seres Therapeutics, Inc.

Marella Thorell named EVP and CFO effective March 25, 2024; David Arkowitz retires as CFO on March 15.
CEO Eric Shaff serves as interim principal financial and accounting officer from March 15 to March 25.
Thorell receives $480,000 base salary, $80,000 sign-on bonus, and option to purchase 700,000 shares.
Arkowitz gets 12 months base salary, COBRA coverage, and $500/hour advisory fee for up to 10 hours/month for 6 months.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Arkowitz

Chief Financial Officer

MCRB · Seres Therapeutics, Inc.

Effective: 2024-03-15
Successor: Marella Thorell
Filed: February 26, 2024, 6:59 PM ET

Mr. Arkowitz’s retirement effective as of March 15, 2024 (the “Retirement Date”).

Appointed

Marella Thorell

Executive Vice President and Chief Financial Officer

MCRB · Seres Therapeutics, Inc.

Effective: 2024-03-25
Filed: February 26, 2024, 6:59 PM ET

On February 24, 2024, the Board of Directors (the “Board”) of Seres Therapeutics, Inc. (the “Company”) appointed Marella Thorell to succeed David Arkowitz as the Company’s Executive Vice President and Chief Financial Officer, effective as of the commencement of her employment with the Company, which is expected to be on or about March 25, 2024 (the “Effective Date”), following Mr. Arkowitz’s retirement effective as of March 15, 2024 (the “Retirement Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Arkowitz retired as Chief Financial Officer at Seres Therapeutics, Inc..

Action: retired
Role: Chief Financial Officer

Exact text from the filing

Mr. Arkowitz’s retirement effective as of March 15, 2024 (the “Retirement Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Marella Thorell was appointed as Executive Vice President and Chief Financial Officer at Seres Therapeutics, Inc..

Action: appointed
Role: Executive Vice President and Chief Financial Officer

Exact text from the filing

On February 24, 2024, the Board of Directors (the “Board”) of Seres Therapeutics, Inc. (the “Company”) appointed Marella Thorell to succeed David Arkowitz as the Company’s Executive Vice President and Chief Financial Officer, effective as of the commencement of her employment with the Company, which is expected to be on or about March 25, 2024 (the “Effective Date”), following Mr. Arkowitz’s retirement effective as of March 15, 2024 (the “Retirement Date”).

View on SEC.gov

Seres Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-045328

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.